ES2531168T3 - Perfiles compuestos de antígenos celulares y proteínas diana de transducción de señales para el análisis y la gestión de la asistencia clínica de los cánceres hematológicos - Google Patents

Perfiles compuestos de antígenos celulares y proteínas diana de transducción de señales para el análisis y la gestión de la asistencia clínica de los cánceres hematológicos Download PDF

Info

Publication number
ES2531168T3
ES2531168T3 ES06827486T ES06827486T ES2531168T3 ES 2531168 T3 ES2531168 T3 ES 2531168T3 ES 06827486 T ES06827486 T ES 06827486T ES 06827486 T ES06827486 T ES 06827486T ES 2531168 T3 ES2531168 T3 ES 2531168T3
Authority
ES
Spain
Prior art keywords
markers
sample
management
analysis
signal transduction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06827486T
Other languages
English (en)
Inventor
Charles Goolsby
Vincent Shankey
David Hedley
James Jacobberger
Stanley Shackney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University Health Network
Case Western Reserve University
Allegheny Singer Research Institute
Beckman Coulter Inc
Northwestern University
Original Assignee
University Health Network
Case Western Reserve University
Allegheny Singer Research Institute
Beckman Coulter Inc
Northwestern University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Health Network, Case Western Reserve University, Allegheny Singer Research Institute, Beckman Coulter Inc, Northwestern University filed Critical University Health Network
Application granted granted Critical
Publication of ES2531168T3 publication Critical patent/ES2531168T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5052—Cells of the immune system involving B-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Un método para establecer un perfil de marcadores compuesto para una muestra procedente de un individuo que se sospecha que tiene un proceso neoplásico, comprendiendo el método las etapas de: (a) hacer reaccionar la muestra biológica con una serie de moléculas de unión, en donde la serie de moléculas de unión contiene dos o más grupos de moléculas de unión específicas para marcadores asociados a una población celular única, en donde los niveles de marcadores y las combinaciones de marcadores identifican poblaciones celulares normales y neoplásicas internas a la muestra; (b) identificar la presencia de poblaciones celulares normales y neoplásicas internas a la muestra mediante la detección de los niveles de marcadores y las combinaciones de marcadores que identifican las poblaciones celulares normales y neoplásicas internas a la muestra, y (c) correlacionar los niveles de marcadores de cada una de las poblaciones celulares normales y neoplásicas con la presencia de una proteína diana para establecer un perfil de marcadores compuesto para una muestra procedente de un individuo que se sospecha que tiene un proceso neoplásico, en donde la proteína diana es una molécula de señalización.
ES06827486T 2005-11-04 2006-11-02 Perfiles compuestos de antígenos celulares y proteínas diana de transducción de señales para el análisis y la gestión de la asistencia clínica de los cánceres hematológicos Active ES2531168T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/267,948 US20070105165A1 (en) 2005-11-04 2005-11-04 Composite profiles of cell antigens and target signal transduction proteins for analysis and clinical management of hematologic cancers
PCT/US2006/043050 WO2007056192A2 (en) 2005-11-04 2006-11-02 Composite profiles of cell antigens and target signal transduction proteins for analysis and clinical management of hematologic cancers

Publications (1)

Publication Number Publication Date
ES2531168T3 true ES2531168T3 (es) 2015-03-11

Family

ID=38004215

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06827486T Active ES2531168T3 (es) 2005-11-04 2006-11-02 Perfiles compuestos de antígenos celulares y proteínas diana de transducción de señales para el análisis y la gestión de la asistencia clínica de los cánceres hematológicos

Country Status (8)

Country Link
US (2) US20070105165A1 (es)
EP (1) EP1943516B1 (es)
JP (4) JP5690048B2 (es)
CN (2) CN103399150B (es)
DK (1) DK1943516T3 (es)
ES (1) ES2531168T3 (es)
PT (1) PT1943516E (es)
WO (1) WO2007056192A2 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1415156B1 (en) 2001-07-10 2009-09-02 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detecting the activation state of multiple proteins in single cells
US7393656B2 (en) 2001-07-10 2008-07-01 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for risk stratification
US7381535B2 (en) * 2002-07-10 2008-06-03 The Board Of Trustees Of The Leland Stanford Junior Methods and compositions for detecting receptor-ligand interactions in single cells
AU2006206159A1 (en) * 2005-01-24 2006-07-27 Massachusetts Institute Of Technology Method for modeling cell signaling systems by means of bayesian networks
ES2318616T3 (es) * 2006-06-01 2009-05-01 Cellzome Ag Metodos para la identificacion de moleculas que interactuan con zap-70 y para la purificacion de zap-70.
CN101802182A (zh) * 2007-08-21 2010-08-11 诺达利蒂公司 用于诊断、预后和治疗方法的方法
US20090269773A1 (en) * 2008-04-29 2009-10-29 Nodality, Inc. A Delaware Corporation Methods of determining the health status of an individual
CN102046196B (zh) * 2008-05-29 2014-07-30 特朗斯吉有限公司 用于选择患者的生物标志物及相关方法
US8399206B2 (en) 2008-07-10 2013-03-19 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
US8227202B2 (en) 2008-07-10 2012-07-24 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
US9506119B2 (en) 2008-11-07 2016-11-29 Adaptive Biotechnologies Corp. Method of sequence determination using sequence tags
EP2364368B1 (en) 2008-11-07 2014-01-15 Sequenta, Inc. Methods of monitoring conditions by sequence analysis
US9528160B2 (en) 2008-11-07 2016-12-27 Adaptive Biotechnolgies Corp. Rare clonotypes and uses thereof
US9365901B2 (en) 2008-11-07 2016-06-14 Adaptive Biotechnologies Corp. Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia
US8748103B2 (en) 2008-11-07 2014-06-10 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
US8628927B2 (en) 2008-11-07 2014-01-14 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
ES2726702T3 (es) 2009-01-15 2019-10-08 Adaptive Biotechnologies Corp Perfilado de la inmunidad adaptativa y métodos para la generación de anticuerpos monoclonales
TWI440719B (zh) * 2009-01-23 2014-06-11 Univ Tokyo 培養細胞的評估方法
EP2259065A1 (en) * 2009-06-03 2010-12-08 Erasmus University Medical Center Rotterdam Methods, reagents and kits for flow cytometric immunophenotyping
WO2010151416A1 (en) 2009-06-25 2010-12-29 Fred Hutchinson Cancer Research Center Method of measuring adaptive immunity
CA3062500C (en) * 2010-12-20 2022-01-18 Cameron K. Tebbi Methods of detecting leukemia/ lymphoma and induction of the same
US10385475B2 (en) 2011-09-12 2019-08-20 Adaptive Biotechnologies Corp. Random array sequencing of low-complexity libraries
EP2768982A4 (en) 2011-10-21 2015-06-03 Adaptive Biotechnologies Corp QUANTIFICATION OF ADAPTIVE IMMUNOCELL GENOMES IN A COMPLEX MIX OF CELLS
US9824179B2 (en) 2011-12-09 2017-11-21 Adaptive Biotechnologies Corp. Diagnosis of lymphoid malignancies and minimal residual disease detection
US9499865B2 (en) 2011-12-13 2016-11-22 Adaptive Biotechnologies Corp. Detection and measurement of tissue-infiltrating lymphocytes
EP3372694A1 (en) 2012-03-05 2018-09-12 Adaptive Biotechnologies Corporation Determining paired immune receptor chains from frequency matched subunits
WO2013158936A1 (en) * 2012-04-20 2013-10-24 Sequenta, Inc Monitoring immunoglobulin heavy chain evolution in b-cell acute lymphoblastic leukemia
HUE029357T2 (en) 2012-05-08 2017-02-28 Adaptive Biotechnologies Corp Preparations and devices for measuring and calibrating amplification distortion in multiplex PCR reactions
EP3330384B1 (en) 2012-10-01 2019-09-25 Adaptive Biotechnologies Corporation Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization
WO2015160439A2 (en) 2014-04-17 2015-10-22 Adaptive Biotechnologies Corporation Quantification of adaptive immune cell genomes in a complex mixture of cells
US9708657B2 (en) 2013-07-01 2017-07-18 Adaptive Biotechnologies Corp. Method for generating clonotype profiles using sequence tags
WO2015134787A2 (en) 2014-03-05 2015-09-11 Adaptive Biotechnologies Corporation Methods using randomer-containing synthetic molecules
US10066265B2 (en) 2014-04-01 2018-09-04 Adaptive Biotechnologies Corp. Determining antigen-specific t-cells
CN107209187B (zh) * 2014-07-11 2021-04-20 国立健康与医学研究所 用于诊断血液癌症的方法
CA2966201A1 (en) 2014-10-29 2016-05-06 Adaptive Biotechnologies Corp. Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from many samples
US10246701B2 (en) 2014-11-14 2019-04-02 Adaptive Biotechnologies Corp. Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture
AU2015353581A1 (en) 2014-11-25 2017-06-15 Adaptive Biotechnologies Corporation Characterization of adaptive immune response to vaccination or infection using immune repertoire sequencing
CA2976580A1 (en) 2015-02-24 2016-09-01 Adaptive Biotechnologies Corp. Methods for diagnosing infectious disease and determining hla status using immune repertoire sequencing
EP3277294B1 (en) 2015-04-01 2024-05-15 Adaptive Biotechnologies Corp. Method of identifying human compatible t cell receptors specific for an antigenic target
CN105223361B (zh) * 2015-08-28 2017-05-17 北京大学人民医院 一种检测急性t淋巴细胞白血病幼稚t细胞的试剂盒、应用及方法
CA2998611A1 (en) * 2015-09-14 2017-03-23 Leukemia Therapeutics, LLC Identification of novel diagnostics and therapeutics by modulating rhoh
CN105652017A (zh) * 2016-02-02 2016-06-08 潍坊三维生物工程集团有限公司 检测lambda轻链含量的试剂盒、方法及用途
RU2642589C2 (ru) * 2016-06-17 2018-01-25 Федеральное государственное автономное образовательное учреждение высшего образования "Балтийский федеральный университет имени Иммануила Канта" (БФУ им. И. Канта) Флуоресцентный способ прогнозирования эффективности химиотерапии у детей, больных острым лимфобластным лейкозом, путем определения концентраций аденозинтрифосфата в митохондриях
US10428325B1 (en) 2016-09-21 2019-10-01 Adaptive Biotechnologies Corporation Identification of antigen-specific B cell receptors
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
CN106771205B (zh) * 2017-01-18 2017-11-21 浙江博真生物科技有限公司 十色抗体组合物及其在白血病淋巴瘤分型中的应用
WO2019051542A1 (en) * 2017-09-12 2019-03-21 The University Of Sydney PREDICTING RESPONSES TO IMMUNOTHERAPY
US11254980B1 (en) 2017-11-29 2022-02-22 Adaptive Biotechnologies Corporation Methods of profiling targeted polynucleotides while mitigating sequencing depth requirements
EP3540631A1 (de) 2018-03-15 2019-09-18 Siemens Healthcare GmbH In-vitro-verfahren zum markierungsfreien bestimmen eines zelltyps einer weissen blutzelle
US20250012798A1 (en) * 2021-11-11 2025-01-09 The General Hospital Corporation Methods for defining stages and progression of amyotrophic lateral sclerosis
CN114624165B (zh) * 2022-03-10 2023-05-23 杭州翔宇医学检验实验室有限公司 血液样本中中性粒细胞cd64的测定方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234816A (en) * 1991-07-12 1993-08-10 Becton, Dickinson And Company Method for the classification and monitoring of leukemias
CN1231761C (zh) * 1998-12-23 2005-12-14 梅德塞克股份有限公司 一种检测装置及鉴定分子的方法
NZ521255A (en) * 2000-03-06 2007-01-26 Univ Kentucky Res Found Methods to impair hematologic cancer progenitor cells and compounds related thereto
US7393656B2 (en) * 2001-07-10 2008-07-01 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for risk stratification
US20030148321A1 (en) * 2001-08-24 2003-08-07 Iris Pecker Methods and kits for diagnosing and monitoring hematopoietic cancers
CA2413475C (en) * 2002-04-25 2010-07-27 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Zap-70 expression as a marker for chronic lymphocytic leukemia/small lymphocytic lymphoma (cll/sll)
EP1678195A4 (en) * 2003-10-08 2008-04-23 The Feinstein Inst Medical Res METHOD AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF CHRONIC LYMPHOCYTIC B-CELL LEUKEMIA
WO2005100999A2 (en) * 2004-04-08 2005-10-27 Cornell Research Foundation, Inc. Functional immunohistochemical cell cycle analysis as a prognostic indicator for cancer
US7803523B2 (en) * 2004-08-27 2010-09-28 University Health Network Whole blood preparation for cytometric analysis of cell signaling pathways

Also Published As

Publication number Publication date
CN103399150B (zh) 2018-07-13
JP2009515170A (ja) 2009-04-09
EP1943516A2 (en) 2008-07-16
US20070105165A1 (en) 2007-05-10
JP2015052621A (ja) 2015-03-19
CN101389959A (zh) 2009-03-18
PT1943516E (pt) 2015-04-20
WO2007056192A3 (en) 2007-07-05
WO2007056192A2 (en) 2007-05-18
CN103399150A (zh) 2013-11-20
EP1943516B1 (en) 2015-01-07
DK1943516T3 (en) 2015-03-16
JP2011221039A (ja) 2011-11-04
JP2014238421A (ja) 2014-12-18
US20100261204A1 (en) 2010-10-14
JP5690048B2 (ja) 2015-03-25

Similar Documents

Publication Publication Date Title
ES2531168T3 (es) Perfiles compuestos de antígenos celulares y proteínas diana de transducción de señales para el análisis y la gestión de la asistencia clínica de los cánceres hematológicos
Greening et al. Proteomic insights into extracellular vesicle biology–defining exosomes and shed microvesicles
EA200971124A1 (ru) Множественный анализ образцов крови
ATE431854T1 (de) Auf bio-barcodes beruhender nachweis von zielanalyten
DK1668368T3 (da) Detektion af histon-modifikation i cellefrie nukleosomer
ATE528648T1 (de) Verfahren zum nachweis antikörper-herstellender zellen
CU23791A3 (es) Método para la producción de proteínas y anticuerpos mejorados
BRPI0315666B8 (pt) dna de a34 e a33 do tipo 3, proteínas, seus anticorpos e métodos de tratamento usando os mesmos
DE60124699D1 (de) Zweirichtungs-durchfluss-zentrifugalmikrofluid-vorrichtungen
EP1687283A4 (en) FOR THE DETERMINATION OF FK506 PROCEDURE AND COMPOSITION
CY1112553T1 (el) Ανοσοπροσδιορισμοι υψηλης ευαισθησιας και κιτια για τον προσδιορισμο πεπτιδιων και πρωτεϊνων βιολογικου ενδιαφεροντος
GT200900255A (es) Sensibilidad mejorada de determinación de perfil de anticuerpos a través de una colocación en capas incrementada de anticuerpo reportero solicitudes relacionadas
NO20044051L (no) Analyse for ACTRIIB-kinase aktivitet
BR112019024602A2 (pt) ensaio para doença associada à célula de plasma
DE602005001302D1 (de) Bestimmung von analytcharakteristika auf der grundlage von bindungseigenschaften
Chen et al. Proteomics profiling of Madin-Darby canine kidney plasma membranes reveals Wnt-5a involvement during oncogenic H-Ras/TGF-β-mediated epithelial-mesenchymal transition
DK1869475T3 (da) In vitro metode til samtidig detektering og identifikation af antibiotika i forskellige klasser og et tilsvarende diagnosekit
WO2003085374A3 (en) Multiplexed assays using electrophoretically separated molecular tags
Wang et al. Highly multiplexed profiling of cell surface proteins on single circulating tumor cells based on antibody and cellular barcoding
ATE545867T1 (de) I-plastin-testverfahren zur in-vitro-diagnose von kolorektalkarzinom
EA202193198A1 (ru) Способы идентификации и количественного определения белка клетки-хозяина
WO2004081025A3 (en) Differential megaplex immunoassay
DE50101520D1 (de) Kompetitives assay-verfahren
WO2002066982A3 (de) Analyse von modifizierungen und demodifizierungen von proteinen mit ubiquintin-verwandten proteinen mittels fret (fluorescence resonance energy transfer)
ES2112211B1 (es) Procedimiento para el estudio del ciclo celular de subpoblaciones de celulas presentes en muestras celulares heterogeneas.